Zydus Receives USFDA EIR for Jarod Injectable Facility; Classified as VAI

Zydus Lifesciences Ltd has received an **Establishment Inspection Report (EIR)** from the U.S. Food and Drug Administration (USFDA) for its **injectable manufacturing facility at Jarod, Vadodara**. The inspection, conducted between **August 25 and September 5, 2025**, has been classified as **Voluntary Action Indicated (VAI)** — a positive compliance outcome indicating that no further regulatory action is required. The inspection was a **follow-up to the Warning Letter** issued by the USFDA on **August 29, 2024**. The VAI classification signals meaningful progress in Zydus’ remediation efforts and is expected to support smoother regulatory approvals and product supplies from the plant going forward. This disclosure has been made under **Regulation 30 of SEBI LODR**, the company said. --- ### **Disclaimer** This article is for informational purposes only and does not constitute investment advice. Please consult your financial advisor before making investment decisions. **Follow for more crisp and reliable financial updates.**